Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
Terminated · Phase 1 · NCT04892017
Conditions: Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
At a glance
- Research payments reported, 2025
- $1.3M
- U.S. investigators named
- 12
- Sites paid
- 16
- Planned or actual enrollment
- 91
About the trial
- Sponsor
- Deciphera Pharmaceuticals, LLC
- Tested
- Inlexisertib (drug), Trametinib (drug), Binimetinib (drug), Sotorasib (drug)
- Dates
- Started 2021-06-15; completion 2026-03-30
- Results posted
- Not yet
This is a multicenter, open label, first in human (FIH) study of inlexisertib as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in participants with advanced or metastatic solid tumors with RAS/MAPK pathway mutation. The study consists of 2 parts, a dose-escalation phase, and an expansion phase.
From ClinicalTrials.gov, last updated 2026-04-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Deciphera Pharmaceuticals Inc. reported $1.3M in research payments for this study in 2025 (481 payments).
Products named: Lumakras
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Nataliya V. Uboha, MD Hematology & Oncology · New Haven, CT
- Danko Martincic, MD Hematology & Oncology · Post Falls, ID
- Raed M. Alrajabi, M.D. Hematology & Oncology · Westwood, KS
- Colin D. Weekes, MD Medical Oncology · Boston, MA
- Moh'd M. Khushman, MD Medical Oncology · Saint Louis, MO
- Sanjay Goel, MD Medical Oncology · New Brunswick, NJ
- Janice M. Mehnert Medical Oncology · New York, NY
- Shivaani Kummar Medical Oncology · Portland, OR
- Ravi K. Amaravadi, MD Medical Oncology · Philadelphia, PA
- Anthony W. Tolcher Medical Oncology · San Antonio, TX
- Andrae L. Vandross, M.D. Medical Oncology · Austin, TX
- Mandana Kamgar, M.D. Hematology & Oncology · Milwaukee, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- New Experimental Therapeutics of San Antonio LLC $227,379
- Rutgers the State University $158,873
- University of Wisconsin System $148,579
- Dana-Farber Mass General Brigham Cancer Care Inc $117,499
- Ohsu Hospital and Clinics, OR $111,351
- New York University $109,669
- Washington University School of Medicine $109,321
- The Washington University $70,164
- The Board of Regents of the University of Wisconsin System $65,191
- The Medical College of Wisconsin Inc $61,209
- Hospital of Univ of Pennsylvania, PA $40,022
- Dana-Farbermass General Brigham Cancer Center Inc $30,651
- Beacon Cancer Care PLLC $23,615
- University of Kansas Medical Center Research Institute Inc $9,340
- Washington University $7,176
- NYU Grossman School of Medicine $1,581
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.